

Ignyta, Inc.  
Form SC 14D9/A  
February 08, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**SCHEDULE 14D-9**

**(Amendment No. 4)**

**Solicitation/Recommendation Statement**

**Under Section 14(d)(4) of the Securities Exchange Act of 1934**

**IGNYTA, INC.**

**(Name of Subject Company)**

**IGNYTA, INC.**

**(Name of Person Filing Statement)**

**Common Stock, par value \$0.0001 per share**

**(Title of Class of Securities)**

**451731103**

Edgar Filing: Ignyta, Inc. - Form SC 14D9/A

**(CUSIP Number of Class of Securities)**

**Jonathan E. Lim, M.D.**

**President and Chief Executive Officer**

**Ignyta, Inc.**

**4545 Towne Centre Court**

**San Diego, California 92121**

**(858) 255-5959**

**(Name, address and telephone number of person authorized to receive notices and communications  
on behalf of the persons filing statement)**

*With copies to:*

**Charles K. Ruck**

**Cheston J. Larson**

**Michael E. Sullivan**

**Latham & Watkins LLP**

**12670 High Bluff Drive**

**San Diego, California 92130**

**(858) 523-5400**

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

### **Purpose of Amendment.**

This Amendment No. 4 (this Amendment) amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 of Ignyta, Inc. (the Company) filed with the Securities and Exchange Commission (the SEC) on January 10, 2018 (as amended or supplemented from time to time, the Schedule 14D-9). The Schedule 14D-9 relates to the cash tender offer by Abingdon Acquisition Corp., a Delaware corporation (Purchaser) and a wholly owned subsidiary of Roche Holdings, Inc., a Delaware corporation (Parent), to purchase all of the issued and outstanding shares of the Company's common stock, par value \$0.0001 per share (the Shares), at a purchase price equal to \$27.00 per Share, net to the seller in cash, without interest and subject to deduction for any required withholding taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated January 10, 2018 (as amended or supplemented from time to time, the Offer to Purchase), and in the related Letter of Transmittal (which, together with the Offer to Purchase, as each may be amended or supplemented from time to time, constitute the Offer). The expiration date of the Offer was at 12:00 midnight, Eastern Time, at the end of the day on Wednesday, February 7, 2018. The Offer is described in a Tender Offer Statement on Schedule TO (as amended or supplemented from time to time, the Schedule TO) filed by Parent and Purchaser with the SEC on January 10, 2018. The Offer to Purchase and Letter of Transmittal are filed as Exhibits (a)(1) and (a)(2), respectively, to the Schedule TO.

Except as otherwise set forth below, the information set forth in the Schedule 14D-9 remains unchanged and is incorporated by reference as relevant to the items in this Amendment. Capitalized terms used and not defined herein shall have the meanings assigned to such terms in the Schedule 14D-9. This Amendment is being filed to reflect certain updates as reflected below.

### **Item 8. Additional Information.**

Item 8 of the Schedule 14D-9 is hereby amended and supplemented by adding the following subsection after the final paragraph of Item 8:

#### **Expiration of the Offer.**

The Offer and withdrawal rights expired at 12:00 midnight, Eastern Time, at the end of the day on February 7, 2018. Citibank, N.A., the depository for the Offer, has advised Parent and Purchaser that, as of the expiration of the Offer, a total of 57,372,887 Shares were validly tendered (excluding all Shares delivered pursuant to guaranteed delivery instructions for which certificates have not yet been delivered) and not properly withdrawn pursuant to the Offer, representing approximately 84.71% of the Shares outstanding at the time of the expiration of the Offer. In addition, Notices of Guaranteed Delivery had been delivered for 3,453,623 Shares, representing approximately 5.10% of the Shares outstanding at the time of the expiration of the Offer. The number of Shares validly tendered (excluding all Shares delivered pursuant to guaranteed delivery instructions for which certificates have not yet been delivered) and not properly withdrawn pursuant to the Offer satisfies the Minimum Condition (as defined in the Merger Agreement). All conditions to the Offer having been satisfied or waived, on February 8, 2018, Purchaser accepted for payment in accordance with the terms of the Offer all Shares that were validly tendered and not properly withdrawn prior to the expiration of the Offer, and payment of the Offer Price for such Shares will be made promptly.

As a result of its acceptance of the Shares tendered in the Offer, Purchaser acquired sufficient Shares to complete the Merger without the affirmative vote of the stockholders of the Company pursuant to Section 251(h) of the DGCL. Following the expiration of the Offer and the acceptance for payment of the Shares, Purchaser was merged with and into the Company, with the Company continuing as the Surviving Corporation and a wholly owned subsidiary of Parent, and each Share issued and outstanding immediately prior to the Effective Time and not tendered pursuant to the Offer (other than any Excluded Shares or Dissenting Shares (each as defined in the Merger Agreement) and the Shares accepted for purchase in the Offer) was automatically converted into the right to receive an amount in cash equal to the Offer Price, net to the seller in cash, without interest and subject to deduction for any required

withholding taxes. The Shares will no longer be listed on the Nasdaq Capital Market and will be deregistered under the Securities Exchange Act of 1934, as amended.

On February 8, 2018, the Company and Roche Holding Ltd, the ultimate parent company of Parent, issued a joint media release relating to the expiration of the Offer and the anticipated consummation of the Merger. The joint media release is attached as Exhibit (a)(17) hereto, and is incorporated herein by reference.

**Item 9. Exhibits.**

Item 9 of the Schedule 14D-9 is hereby amended and supplemented by adding the following exhibit thereto:

**Exhibit**

<b>Number</b>	<b>Description</b>
(a)(17)	Press Release issued by the Company and Roche Holding Ltd, dated February 8, 2018 (incorporated by reference to Exhibit (a)(5)(vii) to the Schedule TO).

**SIGNATURE**

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Ignyta, Inc.**

By: /s/ Jonathan E. Lim, M.D.

Name: Jonathan E. Lim, M.D.

Title: President and Chief Executive  
Officer

Dated: February 8, 2018